Treatment Guideline Recommendations for Tardive Dyskinesia
This slide presentation explores the evolution of treatment approaches for tardive dyskinesia (TD), tracing changes in clinical recommendations over time and outlining the current evidence-based treatment paradigm.
Empty space, drag to resize
Up Next
The Mechanism of Action of VMAT2 Inhibitors
Watch an animated overview of the proposed mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors for the treatment of tardive dyskinesia.
Up Next
DIMD Course: Core Curriculum
In this interactive course series, we will learn more about recognizing and differentiate between different drug-induced movement disorders and review their respective treatment guideline recommendations.
Want to Learn More? Explore Other Learning Paths
DIMDs in Older Adults and Long-Term Care Settings
Focus on VMAT2 Inhibitors
Your Resources on Tardive Dyskinesia and Other DIMDs
These
free educational resources are
sponsored and developed by
Neurocrine Biosciences, Inc.
Discover TD®
In this interactive application, users can differentially diagnose and develop appropriate
management plans for hypothetical, virtual patients with various movement disorders.
DIMD Course
Enroll in this free, virtual self-paced learning platform delving into various clinical aspects of the most common DRBA-induced movement disorders and earn a recognized certificate of completion.
Media Platforms
TD Dialogues® Podcast
Hear from experts in insightful conversations as they discuss the challenges of recognizing TD and share real-world strategies to effectively support patients
in managing symptoms.
This channel features educational videos designed
to further understanding of TD, including content on the proposed mechanism of disease in TD and differentiating TD from drug-induced parkinsonism.
Explore the DIMD Ecosystem Library
Want to explore our collection of DIMD educational resources on your own? Use the link below to view the full content library.
This educational
content was sponsored and developed
by Neurocrine Biosciences, Inc. This
non-CME program is intended to
provide general information about
drug-induced movement disorders and
not medical advice for any particular
patient.
